Tigecycline for severe infections: The gap between the warning and the necessity

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 2, 2011, Pages 454-456

  Curcio, Daniel ^a  

^a Instituto Sacre Cour   (Argentina)

Author keywords

Acinetobacter spp.; Multidrug resistant; Ventilator associated pneumonia

Indexed keywords

CARBAPENEM; DORIPENEM; FOSFOMYCIN; POLYMYXIN; SULBACTAM; TIGECYCLINE;

ABDOMINAL INFECTION; ACINETOBACTER; COMMUNITY ACQUIRED PNEUMONIA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ENDOCARDITIS; FOOD AND DRUG ADMINISTRATION; HUMAN; LETTER; MENINGITIS; PRACTICE GUIDELINE; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEPSIS; TREATMENT OUTCOME; VENTILATOR ASSOCIATED PNEUMONIA;

BACTERIAL INFECTIONS; HUMANS; MINOCYCLINE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 78651412845     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq454     Document Type: Letter

References (12)

1. FDA. FDA Drug Safety Communication: Increased Risk of Death with Tygacil (Tigecycline) Compared to Other Antibiotics Used to Treat Similar Infections. http://www.fda.gov/Drugs/DrugSafety/ucm224370.htm (1 September 2010, date last accessed).
2. Ellis-Grosse EJ, Babinchak T, Dartois N et al. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005; 41 Suppl 5: S341-53.
3. Babinchak T, Ellis-Grosse E, Dartois N et al. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 2005; 41 Suppl 5: S354-67.
4. Tanaseanu C, Bergallo C, Teglia O et al. Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. Diagn Microbiol Infect Dis 2008; 61: 329-38.
5. Freire AT, Melnyk V, Kim MJ et al. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis 2010; 68: 140-51.
6. Solomkin JS, Mazuski JE, Bradley JS et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Surg Infect (Larchmt) 2010; 11: 79-109.
7. Curcio D, Fernández F, Cané A et al. Indications of a new antibiotic in clinical practice: results of the tigecycline initial use registry. Braz J Infect Dis 2008; 12: 198-201.
8. Curcio D, Fernández F, Duret F. Initial use of tigecycline in Argentina. Rev Chilena Infectol 2007; 24: 497-9.
9. Curcio D, Fernández F, Vergara J et al. Late onset ventilator-associated pneumonia due to multidrug-resistant Acinetobacter spp.: experience with tigecycline. J Chemother 2009; 21: 58-62.
10. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999; 115: 462-74.
11. Kollef MH. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis 2000; 31(Suppl 4), S131-8.
12. Michalopoulos A, Falagas ME. Treatment of Acinetobacter infections. Expert Opin Pharmacother 2010; 11: 779-88.